|
| Press Releases |
|
 |
|
| Monday, September 8, 2025 |
|
|
Everest Medicines Announces 2025 Interim Results: 'Dual-Engine' Strategy Driving Strong Synergies Between Commercialization and R&D |
| Everest Medicines (1952.HK) announced its interim results for the six months ended June 30, 2025. The Company's total revenue for the first half of 2025 reached RMB 446 million, representing 48% year-over-year growth, while operating expenses as a percentage of revenue decreased by 40.1 percentage points, reflecting strong operational efficiency. more info >> |
|
| Friday, August 15, 2025 |
|
|
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC |
| Everest Medicines today announced that etrasimod (VELSIPITY(R)) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults (the 'Updated Guidelines'). Etrasimod, an S1P receptor modulator, is recommended for the induction of remission in patients with moderately to severely active UC and for continuation in the maintenance of remission, compared with no treatment after induction of remission. Both recommendations are strong, with a moderate quality of evidence. more info >> |
|
| Thursday, August 14, 2025 |
|
|
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access |
| Everest Medicines (HKEX 1952.HK, 'Everest') today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New Drug Application (NDA) for VELSIPITY' (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC). more info >> |
|
| Friday, August 8, 2025 |
|
|
Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan |
| Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON'. more info >> |
|
| Tuesday, August 5, 2025 |
|
|
NEFECON(R) Receives NMPA Approval for Production Expansion in China, as Everest Medicines Accelerates Accessibility and Capacity Efforts |
| Everest Medicines (HKEX 1952.HK) today announced that the supplemental application for the production expansion of NEFECON has been officially approved by China's National Medical Products Administration (NMPA). more info >> |
|
| Saturday, August 2, 2025 |
|
|
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies |
| Everest Medicines (HKEX: 1952.HK) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash. more info >> |
|
| Friday, July 25, 2025 |
|
|
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million |
| Everest Medicines (HKEX 1952.HK, Everest or the " Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and subscription agreement with the placing agents and its controlling shareholder, CBC Group (the "Sellers"), for a top-up placement of 22,561,000 shares to raise approximately HK$1,572.50 million, representing approximately 6.87% of the total number of Shares in issue as at the date of this announcement, and approximately 6.45% of the total number of Shares in issue. more info >> |
|
| Friday, July 4, 2025 |
|
|
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation |
| Everest Medicines (HKEX: 1952.HK) recently unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day held in Shanghai. The event showcased the company's progress in building a fully integrated and independently operated mRNA platform and highlighted significant breakthroughs across several pipeline programs in cancer and autoimmune diseases. more info >> |
|
| Thursday, June 12, 2025 |
|
|
NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances |
| At the 62nd Congress of the European Renal Association (ERA 2025), Everest Medicines presented new results findings on both NEFECON(budesonide delayed release capsules), the world's first and only approved therapy that directly targets the underlying cause of IgA nephropathy (IgAN), and EVER001, a next-generation covalent reversible BTK inhibitor. more info >> |
|
| Monday, June 9, 2025 |
|
|
Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025 |
| At the 62nd European Renal Association Congress (ERA 2025), Everest Medicines unveiled new clinical data on EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, in patients with primary membranous nephropathy (pMN). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
From Global Collaboration to Energy Innovation: Neutrino Energy Group Publishes the Master Formula of Neutrinovoltaics
Sept 9, 2025 07:00 HKT/SGT
|
|
|
Everest Medicines Announces 2025 Interim Results: 'Dual-Engine' Strategy Driving Strong Synergies Between Commercialization and R&D
Sept 8, 2025 23:12 HKT/SGT
|
|
|
Revenue up 23x! Sigenergy Achieves Profitability in Three Years 
Sept 8, 2025 20:39 HKT/SGT
|
|
|
Emerging designers take the spotlight at YDC 2025
Sept 8, 2025 20:03 HKT/SGT
|
|
|
Radisson Continues to Expand Scope of Gold Mineralization at O'Brien with Latest Drill Results
Sept 8, 2025 18:39 HKT/SGT
|
|
|
Toni Bou Wins 19th Consecutive FIM Trial World Championship Title
Sept 8, 2025 18:53 JST
|
|
|
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
Sept 8, 2025 17:49 JST
|
|
|
Honda to Commercialize UNI-ONE Hands-Free Personal Mobility Device
Sept 8, 2025 15:56 JST
|
|
|
European Dairy Exports from Ireland to Asia Top EUR440 Million in 2024 as Ireland Launches EUR3.2 Million EU Campaign to Strengthen Partnerships
Sept 8, 2025 14:49 HKT/SGT
|
|
|
Mitsubishi Power Signs Contract to Supply Two M701JAC Gas Turbines to O Mon 4 Power Plant
Sept 8, 2025 15:36 JST
|
|
|
Fujitsu develops generative AI reconstruction technology for optimized and energy-efficient AI models based on Takane LLM
Sept 8, 2025 14:28 JST
|
|
|
Yuexiu REIT Disposes of 50% Interest in Yuexiu Financial Tower in Guangzhou and Reorganises the Remaining 50%
Sept 8, 2025 08:02 HKT/SGT
|
|
|
Hong Kong Watch & Clock Fair, Salon de TIME end on a high note
Sept 7, 2025 13:13 HKT/SGT
|
|
|
10th anniversary CENTRESTAGE concludes successfully
Sept 6, 2025 21:36 JST
|
|
|
Mitsubishi Power Receives Contract for Large-Scale GTCC Project with 2,800 MW Total Output for Taiwan's Tung Hsiao Power Plant
Sept 5, 2025 21:47 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
